Cagrilintide vs Tirzepatide

Name: Cagrilintide vs Tirzepatide
Published: 2026-10-24

Updated Oct 24, 20266 sources

Key differences

1REDEFINE 4 (84 weeks): CagriSema 20.2% vs tirzepatide 15 mg 23.6% by treatment regimen, and 23.0% vs 25.5% in adherent people. CagriSema missed non-inferiority.
2Many people add cagrilintide on top of tirzepatide when it stalls, but no human trial has tested that pairing.

Facts from each record, in the same words as their own pages.

Cagrilintide and Tirzepatide side by side
	Cagrilintide	Tirzepatide
Category	Weight loss	GLP-1, Weight loss
Evidence	Some human trials	Strong human trials
FDA status	In clinical trialsRegulatory	FDA approved as Mounjaro +1Regulatory
WADA	Not confirmed	Not prohibited
Half-life	About 7 to 8 days (159 to 195 hours). Levels peak 1 to 3 days after a dose. Measured at 0.16 to 4.5 mg alongside semaglutide.Clinical study	About 5 days (Mounjaro label); 5 to 6 days in people with obesity or sleep apnea (Zepbound label). That is why it is dosed once a week.Regulatory
Routes	Subcutaneous injection	Subcutaneous injection
Reported doses	0.1 to 4.5 mg (subcutaneous injection)	0.25 to 15 mg (subcutaneous injection)
Most cited frequency	Once weekly, added from week 9	Once weekly. Step up 2.5 mg after at least 4 weeks only if needed, then hold the maintenance dose.
Vial sizes	5 mg, 10 mgCompetitor guide	10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mgCompetitor guide
Mixed vial keeps	Keep the mixed vial at 2 to 8 °C, away from light, and use it within about 28 to 30 days.Community-reported	Keep the mixed vial in the fridge and use it within about 28 days.Competitor guide
Protocols on file	13	12

Doses shown are what sources report, labelled by origin. Not medical advice.

6 sources, each checked by date. Record updated Oct 24, 2026. Numbers are restated in our own words and labelled by where they came from.